지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한천식알레르기학회(구 대한알레르기학회) Allergy, Asthma & Immunology Research Allergy, Asthma & Immunology Research Vol.10 No.2
- 발행연도
- 2018.1
- 수록면
- 121 - 130 (10page)
이용수
초록· 키워드
오류제보하기
Purpose: Omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody, has proved to be effective for the treatment of severe asthma. However, there is no direct evidence of effectiveness of omalizumab in Korean patients with severe asthma. We sought to evaluate the real-world effectiveness of omalizumab in Korean adult patients suffering from severe asthma and to identify predictors of favorable response. Methods: A retrospective analysis of electrical medical records was performed on severe allergic asthmatic patients with omalizumab treatment group (OT group) for more than 6 months between March 2008 and February 2016. Propensity score matching was applied to define the standardized treatment control group (STC group) treated without omalizumab. Asthma-related outcomes were compared between the 2 groups, and analyzed before and after omalizumab use in the OT group. Responders to treatment were defined as patients showing >50% reduction in asthma exacerbations and/or systemic steroid requirement during the outcome period. Results: One hundred twenty-four patients with severe asthma (62 in the OT group; 62 in the STC group) were enrolled in the study. Proportion of patients having the reduction of asthma exacerbation (53.2% vs 35.5%, P=0.015) and the rate of responders (67.7% vs 41.9%, P=0.007) were significantly higher in the OT group than in the STC group. Significant reductions were noted in asthma exacerbation (P=0.006), hospitalization (P=0.009), hospitalization days (P=0.006), systemic corticosteroid requirements (P=0.027), and sputum eosinophil count (P=0.031) in OT group compared with STC group. There were no significant differences in changes of forced expiratory volume in the 1 second (FEV1) levels between the 2 groups. No predictors of responders were found for omalizumab treatment. Conclusions: Omalizumab can reduce exacerbations/hospitalization/systemic steroid burst in Korean adult patients with severe asthma.
목차
등록된 정보가 없습니다.
참고문헌 (45)
참고문헌 신청
Chung KF / 2014 / International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma / Eur Respir J 43:343~373
Sullivan PW / 2014 / The relationship between asthma, asthma control and economic outcomes in the United States / J Asthma 51:769~778
Zeiger RS / 2016 / Utilization and costs of severe uncontrolled asthma in a managedcare setting / J Allergy Clin Immunol Pract 4:120~129
Platts-Mills TA / 2001 / The role of immunoglobulin E in allergy and asthma / Am J Respir Crit Care Med 164:S1~S5
Schulman ES / 2001 / Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders / Am J Respir Crit Care Med 164:S6~S11
Sullivan PW / 2014 / The relationship between asthma, asthma control and economic outcomes in the United States / J Asthma 51:769~778
Zeiger RS / 2016 / Utilization and costs of severe uncontrolled asthma in a managedcare setting / J Allergy Clin Immunol Pract 4:120~129
Platts-Mills TA / 2001 / The role of immunoglobulin E in allergy and asthma / Am J Respir Crit Care Med 164:S1~S5
Schulman ES / 2001 / Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders / Am J Respir Crit Care Med 164:S6~S11
이 논문의 저자 정보
최근 본 자료
댓글(0)
0